Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI0101 CART in B-cell Mediated Refractory Autoimmune Diseases
NCT07085676Phase 1Recruiting
- Start
- Sep 2024
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NXC-201 in systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), rheumatoid arthritis (RA) and 5 more. Primary endpoints: Establishment of the initial safety profile of HBI0101 CAR T at 21 days and Confirmation of safety with selected dose at 4 years. Started Sep 2024; status: recruiting.
02
Drugs
NXC-201
03
Conditions
systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07085676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085676.